What is Sweetch?
Founded in 2013, Sweetch operates at the intersection of behavioral science, artificial intelligence (AI), and emotional intelligence (EI) to create a clinically validated digital therapeutics platform. The company specializes in building continuous relationships with patients managing chronic conditions, offering hyper-personalized recommendations tailored to their individual health journeys. Sweetch's solutions are designed for pharmaceutical companies, device manufacturers, payers, and healthcare providers, enabling them to engage with patients at scale and support their health goals effectively.
How much funding has Sweetch raised?
Sweetch has raised a total of $20M across 1 funding round:
Series A
$20M
Series A (2021): $20M with participation from FinTLV Ventures, Entree Capital, Tal-Cap, Noaber, and Kortex Ventures
Key Investors in Sweetch
Entree Capital
Entree Capital backs founders building ambitious technology and product businesses. It partners with teams from the earliest stages through scale up, combining capital with practical guidance and global networks to help companies refine their strategy, grow with discipline and aim for lasting impact.
FinTLV Ventures
Undisclosed investor participating in the funding round.
Tal-Cap
Tal Cap, Inc. does not have significant operations. It focuses on acquiring a viable business. The company is based in Las Vegas, Nevada.
What's next for Sweetch?
The recent major strategic investment signals a pivotal growth phase for Sweetch, likely enabling the company to further scale its operations, enhance its AI and EI capabilities, and expand its market reach. This financing round is expected to accelerate the development and deployment of its digital therapeutics platform, solidifying its position as a leader in personalized chronic condition management and fostering deeper collaborations within the healthcare ecosystem.
See full Sweetch company page
